Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of contract biopharmaceutical manufacturing and development services, is pleased to announce a major expansion of its small molecule manufacturing capabilities with the addition of a new production facility in Visakhapatnam, India. Construction of the 8,500 square meter facility began at the end of July 2020 and is expected to be completed by mid-2022.

To meet current and future customer needs, the new small molecule manufacturing plant doubles the site's production capacity to 310 m 3 for active pharmaceutical ingredients (APIs) and intermediates and has dedicated equipment to manage highly active compounds EPO 4. In addition, the site carried out renovations on the existing laboratory space to accommodate additional R&D activities. It is estimated that the expansion will create at least 60 jobs at the site.

The United States FDA has approved the manufacturing site of Ajinomoto Bio-Pharma Services in India, which has been designed, constructed and is managed according to GMP operating standards and quality systems of the Belgian Aji Bio sites. -Pharma. The company has also successfully supported a number of leading biopharmaceutical companies around the world since its inception in 2011 and continues to win awards for its durability and quality standards.

"We are very pleased to invest in this additional production facility in order to continue to provide quality and cost effective small molecule manufacturing services for our customers," said KVV Raju, Site Operations Manager and CEO of Ajinomoto Bio-Pharma India Pvt. Ltd. “This expansion is a testament to our commitment to the statement of our vision to be a leading, trusted and innovative partner to our customers and our people. "

"The increase in Aji Bio-Pharma's manufacturing capacity in India provides a significant benefit to our small molecule customers, who now have a variety of options to meet their manufacturing needs," said Peter Stuyck , Deputy Managing Director and Director of European Operations of Ajinomoto Bio-Pharma Services. "This expansion optimizes our capabilities across all of our sites and further strengthens Aji Bio-Pharma's commitment to being a global leader in the Contract Development and Processing (CDMO) industry focused on quality offering comprehensive service offers. "

About Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, the United States, Japan and India, and providing services full development, gMP manufacturing (cGMP), as well as aseptic filling finish for small and large molecule APIs and intermediates. Ajinomoto Bio-Pharma Services offers a wide range of innovative platforms and capabilities for preclinical and pilot programs for commercial quantities, including Corynex ® protein expression technology, oligonucleotide synthesis, antibody-drug conjugates (CAMs), highly active APIs (HPAPIs), biocatalysis, flow-through manufacturing and much more. Ajinomoto Bio-Pharma Services is committed to providing a high level of quality and service to meet the needs of its customers. Find out more: www.AjiBio-Pharma.com

Source: prnewswire.com